Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan I So

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 9, 2015
A standardized protocol for identifying and counting lymph nodes harvested by pelvic lymph node dissection at the time of radical cystectomyMichael J Metcalfe, Kourosh Afshar, Alan I So, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlinBoris A Hadaschik, Hans Adomat, Ladan Fazli, et al.
BJU International|April 4, 2008
Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancerBoris A Hadaschik, John Jackson, Ladan Fazli, et al.
American Journal of Clinical and Experimental Urology|January 31, 2019
Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) modelPeter A Raven, Ninadh M D'Costa, Igor Moskalev, et al.
World Journal of Urology|November 9, 2017
A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancerSebastian Karl Frees, Jonathan Aning, Peter Black, et al.
International Journal of Cancer|February 26, 2011
The importance of integrin-linked kinase in the regulation of bladder cancer invasionYoshiyuki Matsui, Kiran Assi, Osamu Ogawa, et al.
BJU International|March 14, 2008
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapyRichard D Sowery, Boris A Hadaschik, Alan I So, et al.
BJU International|November 15, 2008
Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapyClement Mugabe, Boris A Hadaschik, Rajesh K Kainthan, et al.
Stem Cells Translational Medicine|July 8, 2025
Use of adipose-derived stem cells on decellularized bladder scaffolds for functional bladder mucosa regenerationCesar Ulises Monjaras-Avila, Ana Cecilia Luque-Badillo, Nicholas J Carr, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 4, 2020
Defining postoperative ileus and associated risk factors in patients undergoing radical cystectomy with an Enhanced Recovery After Surgery (ERAS) programConnor M Forbes, Ali Cyrus Chehroudi, Miles Mannas, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 9, 2015
A standardized protocol for identifying and counting lymph nodes harvested by pelvic lymph node dissection at the time of radical cystectomyMichael J Metcalfe, Kourosh Afshar, Alan I So, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlinBoris A Hadaschik, Hans Adomat, Ladan Fazli, et al.
BJU International|April 4, 2008
Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancerBoris A Hadaschik, John Jackson, Ladan Fazli, et al.
American Journal of Clinical and Experimental Urology|January 31, 2019
Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) modelPeter A Raven, Ninadh M D'Costa, Igor Moskalev, et al.
World Journal of Urology|November 9, 2017
A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancerSebastian Karl Frees, Jonathan Aning, Peter Black, et al.
International Journal of Cancer|February 26, 2011
The importance of integrin-linked kinase in the regulation of bladder cancer invasionYoshiyuki Matsui, Kiran Assi, Osamu Ogawa, et al.
BJU International|March 14, 2008
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapyRichard D Sowery, Boris A Hadaschik, Alan I So, et al.
BJU International|November 15, 2008
Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapyClement Mugabe, Boris A Hadaschik, Rajesh K Kainthan, et al.
Stem Cells Translational Medicine|July 8, 2025
Use of adipose-derived stem cells on decellularized bladder scaffolds for functional bladder mucosa regenerationCesar Ulises Monjaras-Avila, Ana Cecilia Luque-Badillo, Nicholas J Carr, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 4, 2020
Defining postoperative ileus and associated risk factors in patients undergoing radical cystectomy with an Enhanced Recovery After Surgery (ERAS) programConnor M Forbes, Ali Cyrus Chehroudi, Miles Mannas, et al.
Pageof 10